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Abstract
Background: Since 1995, approval for many new medicinal products has been obtained through a centralized
procedure in the European Union. In recent years, the use of summary measures of population health has become
widespread. We investigated whether efforts to develop innovative medicines are focusing on the most relevant
conditions from a global public health perspective.
Methods: We reviewed the information on new medicinal products approved by centralized procedure from 1995
to 2009, information that is available to the public in the European Commission Register of medicinal products and
the European Public Assessment Reports from the European Medicines Agency. Morbidity and mortality data were
included for each disease group, according to the Global Burden of Disease project. We evaluated the association
between authorized medicinal products and burden of disease measures based on disability-adjusted life years
(DALYs) in the European Union and worldwide.
Results: We considered 520 marketing authorizations for medicinal products and 338 active ingredients. New
authorizations were seen to increase over the period analyzed. There was a positive, high correlation between
DALYs and new medicinal product development (r = 0.619, p = 0.005) in the European Union, and a moderate
correlation for middle-low-income countries (r = 0.497, p = 0.030) and worldwide (r = 0.490, p = 0.033). The most
neglected conditions at the European level (based on their attributable health losses) were neuropsychiatric
diseases, cardiovascular diseases, respiratory diseases, sense organ conditions, and digestive diseases, while globally,
they were perinatal conditions, respiratory infections, sense organ conditions, respiratory diseases, and digestive
diseases.
Conclusions: We find that the development of new medicinal products is higher for some diseases than others.
Pharmaceutical industry leaders and policymakers are invited to consider the implications of this imbalance by
establishing work plans that allow for the setting of future priorities from a public health perspective.
Background
Medicinal product policies are a challenging field in cur-
rent health policy. Medicines are a major determining
factor of population health [1], as the current capacity
of public health to prevent, discontinue, or modify the
natural course of diseases and reduce their symptoms
depends mostly on them.
The pharmaceutical industry is one of the most potent
industrial sectors in developed countries, having a major
impact on national economies and the creation of
e m p l o y m e n to p p o r t u n i t i e sa sw e l la sr e s e a r c hi n v e s t -
ment policies. A proxy variable to establish pharmaceu-
tical research success is the number of authorizations
granted for marketing medicinal products. Regulatory
authorities generally judge the suitability of new treat-
ments in terms of the benefit-risk balance and regulate
commercialization and conditions of use based on qual-
ity, safety, and efficacy criteria. The benefit of medicinal
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decrease in disease burden associated with their use [2],
though additional criteria also can be considered
(e.g., degree of innovation, cost-effectiveness, added
therapeutic value, existence of medicinal products or
other options for the same conditions, and specific
needs of some population groups).
Since early 1995, European Union (EU) authorization
for many new human-use medicinal products has been
obtained through a centralized procedure. This proce-
dure, managed by the European Medicines Agency, is
mandatory for products derived from biotechnology and
other high-technology procedures, those aimed at the
treatment of human immunodeficiency virus/acquired
immunodeficiency syndrome (HIV/AIDS), cancer, dia-
betes, neurodegenerative diseases, autoimmune disor-
ders, viral diseases, and also orphan medicines used to
treat rare diseases. The centralized authorization appli-
cation also can be submitted whenever the medicinal
product involved is a major therapeutic, scientific, or
technical innovation, or is relevant in any other way for
population health [3].
The existence of limited resources for research and
development activities, together with budget restrictions
for funding approved medicinal products, require estab-
lishing explicit criteria to guide debates on priority-set-
ting. In recent years, the calculation and use of
summary measures of population health have become
widespread and influential in global health, as in the
case of disability-adjusted life years (DALYs) [4]. DALYs
for a disease or health condition are calculated as the
sum of years of life lost (YLL) due to premature mortal-
ity in relation to life expectancy and years lived with dis-
ability (YLD). One DALY is equivalent to the loss of one
year of healthy life. DALYs allow the burden of disease
in a population to be measured as the gap between cur-
rent health and an ideal situation where everyone lives
to old age, free of disease and disability. It is an indica-
tion of the unfinished health research agenda and identi-
fies areas where health gains can be made [5]. Thus,
DALYs are designed to guide investment health policies
and to inform global priority setting for health research
activities [6,7].
The aim of this paper is to examine whether medi-
cines development activities in the EU are aimed at the
most relevant conditions from a global public health
perspective, considering burden of disease criteria.
Methods
Study design and data sources
This is an observational, cross-sectional study evaluating
the association between burden of disease measures and
human-use medicinal products authorized in the EU,
establishing whether the development of innovative
medicinal products changes with disease burden in dif-
ferent populations. With information from public
sources [8,9] accessible through the Internet, we created
an authorization database based on the cohort of medic-
inal products authorized by EU centralized procedure
during the period from January 1995 (the date when the
European Medicines Agency was created) to December
2009. We specifically examined: the European Commis-
sion Register of medicinal products [8] and the
European Public Assessment Reports (EPARs) for
authorized medicinal products [9]. We collected the fol-
lowing information: year of approval, name of the med-
icinal product, active ingredients (new chemical
entities), main indication, disease seriousness, type
of intervention, and other variables when appropriate
(e.g., new mechanism, biotechnological/biological pro-
duct, orphan medicinal product, fixed-dose combina-
tions or drug associations, generics and similar
biological medicinal products - also called “biosimilars”).
We used the following definitions:
Main indication: This was defined as the first approval
for a given drug, and later approvals were considered
extensions.
Disease seriousness: A disease was classified as (chronic)
serious if it is fatal, requires hospitalization, or is life-threa-
tening or heavily disabling (e.g., myocardial infarction,
dementia, pneumonia); as nonserious (e.g., erectile
dysfunction, allergic rhinitis); or as a risk factor for serious
disease (e.g., obesity, hypertension, anemia associated with
chronic renal failure).
Type of intervention: This was defined as prevention,
diagnosis, treatment, or palliative care/rehabilitation.
New mechanism of action: A mechanism was defined as
new if the primary pharmacodynamic target (e.g., receptor)
and drug-target interaction differed from existing drugs.
When a medicine belonged to a new therapeutic class
and the mechanism of action was unknown, it was classi-
fied as new.
Medicinal products for which marketing authorization
was “withdrawn, suspended and/or not renewed” during
the study period were excluded from the primary
analysis.
The Pediatric Regulation (Regulation EC No 1901/
2006) came into place to improve the health of children
in the EU without subjecting children to unnecessary
trials or delaying the authorization of medicinal pro-
ducts for use in adults. Since then, all patented medic-
inal products submitted for a marketing authorization
(or line extension) in the EU need to have an agreed
drug development plan, namely a Pediatric Investigation
Plan (PIP). Thus, to create a complementary assessment
of medicines development activities related to pediatric
needs, the European Medicines Agency website http://
www.ema.europa.eu was searched for information with
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used for pediatric pharmaceutical output). We also
included decisions agreeing on a PIP, with or without
partial waiver(s) and or deferral(s). These data provide
information about what medicinal products are in the
pipeline and may help illuminate the extent to which
efforts are focusing on the development of innovative
medicines for children.
For each disease group, we included morbidity and
mortality data according to the Global Burden of Dis-
ease study [10,11]. This project was conducted by the
World Bank, the World Health Organization (WHO),
and the Harvard School of Public Health to quantify the
burden of disease and injury on human populations and
to gather information on prevalence, incidence, severity,
disability, and mortality for more than 100 causes [4,10].
Burden of disease, measured in DALYs and mortality,
refers to the most recent estimations available at the
time of analysis. In brief, this report used the data for
the world population - by income categories as defined
by the World Bank - and for the 25 EU Member States
(EU-25) in 2004 [11]. The main therapeutic indications
for medicinal products were then matched with the
categories of the disease classification system defined in
the Global Burden of Disease study [10].
Statistical analysis
We established the direction and strength of association
between human-use medicinal products authorized dur-
ing the study period and burden of disease measures. In
a subanalysis regarding pharmaceutical development
output for pediatric needs, we measured the associations
between the burden of disease in children under
15 years of age - the pediatric age group reported in the
estimates for WHO countries [10,11] - and the decisions
of the European Medicines Agency’s Pediatric Commit-
tee agreeing on a PIP for an individual medicinal pro-
duct. Using the STATA package (Version 10, StataCorp
LP, College Station, TX, USA), we calculated nonpara-
metric Spearman rank correlation coefficients (r). The
statistical significance level was set at a value of 0.05
(a confidence level of 95%).
Results
We included 520 marketing authorizations for medicinal
products in the analysis, corresponding to 338 active
ingredients (Figure 1). Table 1 describes the main char-
acteristics and distribution of the new medicinal pro-
ducts in development. From 1995 to 2009, the total
number of new authorizations by EU centralized proce-
dure increased. Furthermore, the ratio between the
number of marketing authorizations and the number of
active ingredients also increased over the period of
study. We found that medicinal products covered
mainly therapeutic and preventive interventions aimed
at serious diseases.
Table 2 shows the main data on the output of phar-
maceutical development and disease burden measures
by cause and region. The indication of new active ingre-
dients was mainly malignant neoplasms (17.5%), infec-
tious and parasitic diseases (16.6%), blood and
endocrine disorders (12.7%), neuropsychiatric conditions
(10.9%), cardiovascular diseases (8.6%), diabetes mellitus
(7.4%), and musculoskeletal diseases (7.1%).
In general, a high association was found between disease
burden and the development of medicinal products in the
EU-25 (r = 0.619, p = 0.005), and a moderate association
at the global level (r = 0.490, p = 0.033) (Table 3). How-
ever, these associations do not hide disproportionality rela-
tionships between the various disease categories (Figures 2
and 3). In the EU-25, the greatest disproportionality was
seen for infectious and parasitic diseases, blood and endo-
crine disorders, diabetes mellitus and genitourinary dis-
eases (all of them overrepresented related to the burden
they generate). Conversely, neuropsychiatric conditions,
cardiovascular diseases, sense organ conditions, respiratory
diseases, or digestive diseases were underrepresented
(Figure 2). Meanwhile, the most neglected conditions
worldwide (based on DALYs) were mainly perinatal condi-
tions, respiratory infections, diseases of the sense organs,
respiratory diseases, or digestive diseases (Figure 3).
We found differences between regions and countries,
with better associations with DALYs than with mortality
(Table 3). By region, the associations were stronger in
the EU-25 (DALYs: r = 0.619, p = 0.005) than in mid-
dle-low-income countries (DALYs: r = 0.497, p = 0.030)
or globally (DALYs: r = 0.490, p = 0.033), and similar
to those of high-income countries (DALYs: r = 0.606,
p = 0.006). Differences also were found within the EU,
577 marketing authorisations granted (356 
active ingredients) by EU centralized 
procedure, 1995-2009
522 marketing authorisations granted (339 
active ingredients) selected for the analysis
55 marketing authorisations withdrawn, suspended and/or not 
renewed (45 active ingredients) excluded from the analysis
2 marketing authorisations granted to medicinal products 
with no specific indication (1 active ingredient) excluded
520 marketing authorisations granted (338 
active ingredients) finally included in the 
analysis with disease burden measures
Figure 1 Pharmaceutical output selection. Marketing
authorizations granted (and active ingredients) by EU
centralized procedure, 1995-2009.
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recently joining the EU (DALYs: r = 0.499, p = 0.030)
than in the 15 countries initially established (DALYs:
r = 0.603, p = 0.006). By countries, the values were
for mortality: from r = 0.304 (p = 0.206) in Poland to
r = 0.558 (p = 0.013) in Luxembourg; while for DALYs,
the values were from r = 0.376 (p = 0.113) in Finland to
r = 0.663 (p = 0.002) in Portugal.
Additionally, we examined the pharmaceutical devel-
opment output related to pediatric needs (Tables 4 and
5). We identified 103 PIPs agreed to in the EU after the
Pediatric Regulation was introduced. No evidence of
association was found between the number of PIPs and
the regional burden of disease in children under 15
years (DALYs: r = 0.079, p = 0.779; mortality: r =
0.404, p = 0.135).
Discussion
Our analysis for the period 1995-2009 uses the cohort of
human-use medicinal products authorized by centralized
procedure to show that the development of medicinal
products is higher for some diseases than others. The
three main therapeutic areas in terms of number of
innovative medicinal products were oncology, infectious
and parasitic diseases, and blood and endocrine disor-
ders (accounting for 46.8% of active ingredients and
38.4% of marketing authorizations). The results also
showed a moderate to high association between the
development of medicinal products and disease burden
measures for the main disease categories, though some
conditions appear to be neglected (related to the health
loss generated in the population) as in the case of neu-
ropsychiatric, cardiovascular, respiratory, sense organ,
digestive, perinatal diseases, etc. On the contrary, the
number of agreed PIPs was not associated with the
number of DALYs and deaths among children under
15 years. Therefore, the review of PIPs suggested again
that some disease conditions were more neglected than
others (related to pediatric health needs), such as peri-
natal conditions, congenital anomalies, and neuropsy-
chiatric diseases.
The European Medicines Agency is the regulatory
authority providing the Member States and the institu-
tions of the EU with scientific advice on quality, safety,
and efficacy of medicines. Medicinal products author-
ized by the centralized procedure can be automatically
marketed in all EU Member States. Barbui and
Garattini [12] highlighted some issues that can adversely
affect assessment of medicinal products for some dis-
eases. First, the centralized procedure is not mandatory
for all human-use medicinal products, and different
authorization procedures in the EU (e.g., centralized
Table 1 Main characteristics and distribution of the marketing authorizations of medicinal products for human use
and active ingredients (NCEs), 1995-2009
Period 1995-1999 Period 2000-2004 Period 2005-2009
Characteristics Num. of
authorizations (%)
Num. of
NCEs (%)
Num. of
authorizations (%)
Num. of
NCEs (%)
Num. of
authorizations (%)
Num. of
NCEs (%)
Total 86 (100) 70 (100) 143 (100) 116 (100) 291 (100) 152 (100)
Type of intervention
Prevention 15 (17.4) 12 (17.1) 13 (9.1) 7 (6.0) 56 (19.2) 19 (12.5)
Diagnosis 4 (4.6) 3 (4.3) 4 (2.8) 4 (3.4) 5 (1.7) 5 (3.3)
Treatment 65 (75.6) 53 (75.7) 122 (85.3) 101 (87.1) 214 (73.5) 120 (78.9)
Palliative care/
rehabilitation
2 (2.3) 2 (2.9) 4 (2.8) 4 (3.4) 16 (5.5) 8 (5.3)
Disease seriousness
Serious disease 59 (68.6) 50 (71.4) 104 (72.7) 86 (74.1) 191 (65.6) 109 (71.7)
Nonserious disease 11 (12.8) 9 (12.9) 21 (14.7) 17 (14.6) 44 (15.1) 20 (13.2)
Risk factor for serious
disease
16 (18.6) 11 (15.7) 18 (12.6) 13 (11.2) 56 (19.2) 23 (15.1)
New mechanism of action 18 (20.9) 17 (24.3) 44 (30.8) 42 (36.2) 32 (11.0) 27 (17.8)
Fixed-dose combinations 6 (7.0) 4 (5.7) 13 (9.1) 8 (6.9) 37 (12.7) 18 (11.8)
Biotechnological/
biological product
27 (31.4) 24 (34.3) 52 (36.4) 41 (35.3) 77 (26.5) 42 (27.6)
Orphan medicinal
product*
-- 18 (12.6) 18 (15.5) 39 (13.4) 39 (25.7)
Generic and/or
“biosimilar"*
---- 69 (23.7) -
Data do not sum to 100% because of rounding errors *The European Commission granted marketing authorizations for: orphan medicinal products in 2001,
“biosimilar” products in 2006, and generic products in 2007. NCEs = New chemical entities.
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procedures) can result in heterogeneity in terms of
authorized medicinal products between countries. Sec-
ond, new medicinal products can be evaluated without
needing to establish comparisons to active treatments.
Therefore, a medicinal product can be marketed if it
shows a difference versus a placebo (dummy treatment),
and in cases where this is not ethical, demonstrating
“noninferiority” versus an active comparator is per-
mitted. This can cause uncertainty on the therapeutic
role of new medicinal products, as suggested in recent
reviews on cancer [13,14], cardiovascular [15], antirheu-
matic [16], and central nervo u ss y s t e mt r e a t m e n t s[ 1 7 ] .
From a public health perspective [18-20], the therapeu-
tic value and degree of innovation of medicinal pro-
ducts could also be considered, referring to their
added value related to other available options. Some of
the items to be highlighted in this approach would
include: the relative or incremental value compared
with the available alternatives, the evaluation under
real conditions of use (comparative effectiveness and
safety), or even its incremental costs (efficiency or
cost-effectiveness), which is of high value for guiding
pricing and reimbursement decisions following the
marketing authorization [21,22].
While there is general concern about the lack of inno-
vation in the development of medicinal products, there
is an increased number of active ingredients and of new
marketing authorizations. The apparent increase in cen-
trally authorized generics, “biosimilars,” and fixed-dose
combinations observed over the study period may have
contributed to this situation. Furthermore, these results
may be a sign of the failure of the pharmaceutical mar-
ket to anticipate unmet needs and consumer demand.
This analysis also involves some limitations. First, the
assessment refers only to medicinal products for human
use authorized by centralized procedure. Though there
are other alternative procedures, we assumed that the
cohort of medicinal products selected here can be con-
sidered to be representative of current pharmaceutical
innovation. Second, to measure pharmaceutical develop-
ment output, we used for the primary analyses the data
on new marketing authorizations and of active ingredi-
ents. Despite being significant measures expressing the
productivity of research and development activities,
other measures could have been selected instead
Table 2 Distribution of medicinal products authorized for human use by therapeutic area (1995-2009) and burden of
disease (as measured by disability-adjusted life years and mortality)
Disease conditions Medicinal products for human use, 1995-2009 Burden of disease in the population
Marketing authorizations NCEs Mortality per 10
6 (%) DALYs per 10
6 (%)
Number (%) Number (%) Worldwide EU-25 Worldwide EU-25
Communicable diseases 100 (19.2) 75 (22.2) 18.0 (30.6) 0.2 (4.8) 604.0 (39.7) 2.7 (4.6)
Infectious and parasitic diseases 68 (13.1) 56 (16.6) 9.5 (16.2) .06 (1.3) 302.1 (19.8) 0.9 (1.6)
Respiratory infections 19 (3.6) 8 (2.4) 4.3 (7.2) 0.1 (3.1) 97.8 (6.4) 0.6 (1.0)
Maternal conditions 11 (2.1) 9 (2.7) 0.5 (0.9) .00 (0.0) 38.9 (2.6) 0.2 (0.3)
Perinatal conditions 2 (0.4) 2 (0.6) 3.2 (5.4) .01 (0.3) 126.4 (8.3) 0.6 (1.0)
Noncommunicable diseases 419 (80.6) 262 (77.5) 35.0 (59.6) 4.0 (89.9) 731.6 (48.0) 51.1 (87.4)
Malignant neoplasms 73 (14.0) 59 (17.5) 7.4 (12.6) 1.2 (27.0) 77.8 (5.1) 9.7 (16.6)
Other neoplasms 1 (0.2) 1 (0.3) 0.2 (0.3) .03 (0.8) 1.9 (0.1) 0.2 (0.3)
Diabetes mellitus 46 (8.8) 25 (7.4) 1.1 (1.9) 0.1 (2.3) 19.7 (1.3) 1.5 (2.5)
Blood and endocrine disorders 59 (11.3) 43 (12.7) 0.3 (0.5) .03 (0.7) 10.4 (0.7) 0.7 (1.3)
Neuropsychiatric conditions 66 (12.7) 37 (10.9) 1.3 (2.1) 0.2 (4.8) 199.3 (13.1) 14.3 (24.5)
Sense organ diseases 11 (2.1) 10 (3.0) 0.0 (0.0) 0.0 (0.0) 86.9 (5.7) 4.4 (7.5)
Cardiovascular diseases 75 (14.4) 29 (8.6) 17.1 (29.0) 1.8 (42.0) 151.4 (9.9) 10.2 (17.4)
Respiratory diseases 11 (2.1) 6 (1.8) 4.0 (6.9) 0.2 (4.9) 59.0 (3.9) 3.1 (5.4)
Digestive diseases 10 (1.9) 4 (1.2) 2.0 (3.5) 0.2 (4.8) 42.5 (2.8) 2.7 (4.6)
Genitourinary diseases 23 (4.4) 13 (3.8) 0.9 (1.6) .07 (1.6) 14.7 (1.0) 0.5 (0.8)
Skin diseases 7 (1.3) 7 (2.1) .07 (0.1) 0.0 (0.2) 4.0 (0.3) 0.1 (0.2)
Musculoskeletal diseases 31 (6.0) 24 (7.1) 0.1 (0.2) .02 (0.5) 30.9 (2.0) 2.6 (4.4)
Congenital anomalies 5 (1.0) 3 (0.9) 0.4 (0.7) .01 (0.3) 25.3 (1.7) 0.6 (1.0)
Oral conditions 1 (0.2) 1 (0.3) 0.0 (0.0) 0.0 (0.0) 7.9 (0.5) 0.4 (0.7)
Unintentional injuries (poisoning) 1 (0.2) 1 (0.3) 0.3 (0.6) .01 (0.2) 7.5 (0.5) 0.2 (0.3)
Total 520 (100) 338 (100) 58.8 (100) 4.4 (100) 1,523.2 (100) 58.4 (100)
Data do not sum to 100% because of rounding errors. Burden of disease data are from World Health Organization 2009 for the year 2004. Burden of disease is
measured by mortality and disability-adjusted life years (DALYs). NCEs = New chemical entities. EU-25 = all 25 EU countries in 2004.
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tures per therapeutic area or per DALY lost, etc.). The
number of new marketing authorizations and of active
ingredients may not be necessarily an indication of the
interest in a given disease as they may represent drugs
that are structurally similar to already existing ones with
only minor pharmaceutical differences (so-called “me-
too” drugs). In addition, broader health status measures
favorably reflect the results of biomedical research
investments. These include lower DALYs lost, lower
death rates for chronic diseases, longer life expectancy
and improved quality of life for elderly people; and
more effective and earlier disease detection [23]. Third,
sometimes a medicinal product can be authorized for
more than one therapeutic indication in various condi-
tions or diseases (e.g., an anticancer agent for the treat-
ment of solid tumors and hematological malignancies, a
psychoanaleptic indicated for depression and diabetic
peripheral neuropathic pain, etc.). For the purpose of
our analysis, the information can be imperfect as the
main indication was chosen. However, we think using
the main disease groups and categories instead of subca-
t e g o r i e sw h i l ea l s ou s i n gac omprehensive, consistent,
and exclusive classification system enabled us to reduce
misclassification bias, making the main findings robust.
The approach of this analysis has been used in other
areas, such as health services research [24-26]. Surpris-
ingly, little attention has been paid to analyzing dispro-
portionality among population health needs and the
development of innovative medicinal products. The par-
ties interested in some diseases or interventions often
mention the lack of funds for their disease or interven-
tion without considering the global health implications.
A previous report concluded that health research does
not reflect the global burden of disease, with less than
10% of resources invested in the study of diseases that
contribute 90% of the global burden of disease, also
known as the “10/90 gap” [27]. It has been argued that
the pharmaceutical industry appears unwilling to fund
development of new medicinal products aimed at health
needs in middle-low-income countries because the pro-
spects for financial gain for the industry are limited [28].
Our analysis provides information on this matter. We
found that nearly 80% (262/338) of the new medicinal
products are aimed at less than 50% of health losses
(expressed in DALYs) in the world, accounting for 90%
of DALYs in high-income countries, as in the case of
the EU-25. Although the data appear to indicate that
the “10/90 gap” is decreasing, there are still neglected
global health needs.
It is noteworthy to mention that the availability of
medicines depends partially on the state of research on
a particular disease. Indeed, some diseases may require a
more significant investment of resources to develop
innovative medicines. The la c ko fn o v e lm e d i c i n a lp r o -
ducts in specific areas may also indicate that there are
medicines under patent protection (marketing exclusiv-
ity) or that the pharmaceutical market is saturated in
those areas. Therefore, the financial rewards for the
pharmaceutical industry to develop medicines of rele-
vant therapeutic value may not be profitable enough to
assume the risky nature of their investments.
On the other hand, the granting of marketing approval
does not necessarily translate into improved availability
of medicines. In fact, access to medicines is far from
Table 3 Associations of active ingredients (NCEs) with
burden of disease (as measured by disability-adjusted
life years and mortality) by region and country
Mortality DALYs
Coefficient
r
p-
value
Coefficient
r
p-
value
Worldwide .417 .076 .490* .033
High-income .485* .035 .606** .006
Low- and middle-
income
.413 .079 .497* .030
EU-25 .449 .054 .619** .005
EU-15 .492* .032 .603** .006
Austria .491* .033 .619** .005
Belgium .554* .014 .637** .003
Denmark .441 .059 .562** .012
Finland .334 .162 .376 .113
France .555* .014 .612** .005
Germany .455 .050 .657** .002
Greece .495* .031 .610** .006
Ireland .484* .036 .504* .028
Italy .455* .558 .641** .003
Luxembourg .558* .013 .585** .008
Netherlands .483* .036 .534* .018
Portugal .476* .039 .663** .002
Spain .518* .023 .620** .005
Sweden .452 .052 .550* .015
United Kingdom .476* .039 .564* .012
EU-10 .304 .206 .499* .030
Cyprus .425 .070 .627** .004
Czech Republic .337 .159 .487* .035
Estonia .316 .188 .475* .040
Hungary .373 .116 .501* .029
Latvia .248 .306 .513* .025
Lithuania .207 .394 .404 .086
Malta .328 .171 .578** .010
Poland .304 .206 .571* .011
Slovakia .326 .173 .547* .015
Slovenia .344 .149 .492* .032
*p-value < .05 (bilateral); ** p-value < 0.01 (bilateral).
EU-25 = all 25 EU countries in 2004. EU-15 = established EU countries. EU-10
= 10 newly joined EU countries. Data represent Spearman’s rank correlation
coefficients (r). DALYs = disability-adjusted life years.
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ment are still matters for countries to consider accord-
ing to their government policies, health resources, and
public health systems [14]. This is particularly important
in middle-low-income countries, where there is an
access problem either for issues linked to the cost of
medicines acquisition, defective health structures, or
underdiagnosis. For example, about 5 million people die
every year worldwide because of communicable diseases
such as diarrheal conditions, HIV/AIDS, tuberculosis,
and malaria [10], even though these diseases are treatable
(or at least preventable) with current interventions. In
the case of noncommunicable diseases such as diabetes
or other cardiovascular risk factors (e.g., hypertension,
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Page 7 of 10obesity, smoking, etc.) for which interventions (not only
medicines) are available, many health systems cannot
meet population needs in the poorest communities.
Chronic noncommunicable diseases in developing coun-
tries are not just diseases of the elderly, since cardiovas-
cular diseases account for as many deaths in young and
middle-aged adults as HIV/AIDS. Also, chronic diseases
affect a much higher proporti o no fp e o p l ei nd e v e l o p i n g
countries during their prime working years than they do
in developed countries [29]. There are several challenges
to public health that require a new global and regional
strategic approach, including the availability of medicines
for current unmet medical needs, among others [30,31].
Some investigators have suggested incentives for new
medicinal products that are effective against diseases of
high societal burden or gravity for populations. These
include incentives for novelty, comparative effectiveness
and safety, extended patent life, and pricing enhance-
ments for drugs aimed at particular public health needs.
Such incentives have been used successfully for vaccines
and low-prevalence (orphan) diseases [29].
Table 4 Main characteristics of the Pediatric Investigation
Plans (PIPs) and related active ingredients (NCEs)
Characteristics Num. of PIPs
(%)
Num. of NCEs
(%)
Total 103 (100) 95 (100)
Type of intervention
Prevention 11 (10.7) 8 (8.4)
Diagnosis - -
Treatment 85 (82.5) 80 (84.2)
Palliative care/rehabilitation 7 (6.8) 7 (7.4)
Disease seriousness
Serious disease 73 (70.1) 66 (69.5)
Nonserious disease 20 (19.4) 19 (20.0)
Risk factor for serious disease 10 (9.7) 10 (10.5)
New mechanism of action 21 (20.4) 20 (21.0)
Fixed-dose combinations 11 (10.7) 11 (11.6)
Biotechnological/biological
product
31 (30.1) 25 (26.3)
Orphan medicinal product 16 (15.5) 16 (16.8)
Data do not sum to 100% because of rounding errors. PIPs = Pediatric
Investigation Plans. NCEs = New chemical entities with an agreed PIP. Source
of the data: http://www.ema.europa.eu (search until September 2010).
Table 5 Distribution of pharmaceutical output related to pediatric needs by therapeutic area and burden of disease in
children under 15 years (as measured by disability-adjusted life years and mortality)
Disease conditions Pharmaceutical output related to pediatric needs Burden of disease in children under 15 years
PIPs NCEs Mortality per 10
6 (%) DALYs per 10
6 (%)
Number (%) Number (%) Worldwide EU-25 Worldwide EU-25
Communicable diseases 20 (19.4) 19 (20.0) 10.1 (84.6) 0.1 (43.7) 406.5 (74.1) 0.9 (24.6)
Infectious and parasitic diseases 12 (11.6) 12 (12.6) 4.6 (38.6) .01 (3.4) 176.5 (32.2) 0.1 (3.8)
Respiratory infections 5 (4.8) 4 (4.2) 2.1 (17.3) .01 (2.0) 76.2 (13.9) .07 (1.9)
Maternal conditions 2 (1.9) 2 (2.1) .00 (0.0) .00 (0.0) 0.5 (0.1) .00 (0.0)
Perinatal conditions 1 (1.0) 1 (1.0) 3.2 (26.8) 0.1 (38.3) 126.4 (23.1) 0.6 (16.2)
Noncommunicable diseases 83 (80.6) 76 (80.0) 1.0 (8.1) 0.1 (44.3) 93.5 (17.1) 2.3 (64.2)
Malignant neoplasms 16 (15.5) 15 (15.8) .09 (0.7) .02 (7.1) 3.2 (0.6) .09 (2.4)
Other neoplasms - - .01 (0.1) .00 (0.9) 0.3 (0.1) .01 (0.3)
Diabetes mellitus 9 (8.7) 7 (7.4) .01 (0.1) .00 (0.1) 0.3 (0.1) .00 (0.1)
Blood and endocrine disorders 15 (14.6) 14 (14.7) .05 (0.4) .01 (3.2) 3.4 (0.6) 0.1 (3.8)
Neuropsychiatric conditions 9 (8.7) 9 (9.5) .08 (0.6) .02 (4.8) 30.6 (5.6) 0.9 (24.6)
Sense organ diseases 1 (1.0) 1 (1.0) .00 (0.0) .00 (0.0) 4.5 (0.8) 0.1 (3.6)
Cardiovascular diseases 12 (11.6) 11 (11.6) 0.1 (1.0) .01 (2.7) 5.1 (0.9) .04 (1.1)
Respiratory diseases 4 (3.9) 4 (4.2) .06 (0.5) .00 (1.1) 9.2 (1.7) 0.3 (9.0)
Digestive diseases 2 (1.9) 1 (1.0) 0.1 (1.1) .00 (1.0) 6.5 (1.2) .05 (1.7)
Genitourinary diseases 2 (1.9) 2 (2.1) .03 (0.3) .00 (0.2) 1.6 (0.3) .01 (0.2)
Skin diseases 6 (5.8) 6 (6.3) .00 (0.0) .00 (0.0) 0.9 (0.2) .00 (0.1)
Musculoskeletal diseases 7 (6.8) 6 (6.3) .00 (0.0) .00 (0.2) 1.6 (0.3) .03 (0.9)
Congenital anomalies - - 0.4 (3.3) .07 (23.1) 24.1 (4.4) 0.5 (14.5)
Oral conditions - - .00 (0.0) .00 (0.0) 2.2 (0.4) .08 (2.2)
Unintentional injuries (poisoning) - - .03 (0.3) .00 (0.2) 1.2 (0.2) .00 (0.1)
Total 103 (100) 95 (100) 11.9 (100) 0.3 (100) 548.4 (100) 3.6 (100)
Data do not sum to 100% because of rounding errors. Burden of disease data are from World Health Organization 2009 for the year 2004. Burden of disease in
children under 15 years is measured by mortality and disability-adjusted life years (DALYs). PIPs = Pediatric Investigation Plans. EU-25 = all 25 EU countries in
2004. *NCEs = new chemical entities with an agreed PIP.
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Page 8 of 10The European Medicines Agency has recently
launched a public consultation on its future actions,
based on which it intends to set priorities for coming
years. European and international agencies, including
medical and patient organizations, the pharmaceutical
industry, and citizens have been invited to participate in
the document, “Road Map to 2015” [31], including
debating how to approach public health needs, promot-
ing research on medicinal products in unmet medical
needs areas, or for rare and neglected diseases, providing
innovative proposals for drug development.
In this paper, we intended to provide information
based on the outcomes of decisions made during 15
years in the European setting. Pharmaceutical industry
leaders and policymakers are invited to consider the
implications of the imbalance explored in this paper,
establishing work plans that allow for defining future
priorities from a public health perspective.
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